J&J sees device growth through new products, emerging markets

Thu May 22, 2014 12:10pm EDT

Products made by Johnson & Johnson are displayed for sale on a store shelf in Westminster, Colorado April 14, 2009. REUTERS/Rick Wilking

Products made by Johnson & Johnson are displayed for sale on a store shelf in Westminster, Colorado April 14, 2009.

Credit: Reuters/Rick Wilking

(Reuters) - Johnson & Johnson said on Thursday it planned to file for approvals of more than 30 major products by the end of 2016 as the diversified healthcare company looks to restore growth to a medical device and diagnostics division that has been overshadowed by its drugs business in recent years.

J&J said it was positioned for growth through new products recently launched and those in its pipeline and would place significant focus on fast-growing emerging markets, particularly China and Russia.

"We are capitalizing on our established footprint to grow and expand our overall business (in China)," Chief Financial Officer Dominic Caruso said during a device business review for analysts and investors at its New Jersey headquarters.

J&J said it has the number one diabetes business in China, with a population that includes a quarter of the world's diabetics. The company said it has signed an exclusive equipment manufacturing agreement with Nova Biomedical Corp to sell blood glucose testing systems to hospitals in China, which account for about 60 percent of diabetes care in the country.

The company also said it has identified a large unmet need for minimally invasive surgical products for lung cancer surgeries in China that it believes it can address.

In Russia, the company said its vision care unit is developing new business models focusing on both eye care professionals and consumers.

The company is hoping to jumpstart growth in the device and diagnostics business that saw flat first-quarter sales of $7.06 billion. J&J's pharmaceuticals division by comparison grew nearly 11 percent in the first quarter led by new drugs for cancer, hepatitis C and to prevent blood clots.

Gary Pruden, head of global surgical products, forecast compound annual growth of 4 percent to 6 percent from 2013-2018 for his division.

He projected between 21 and 25 new product launches over the next 18 months to two years in areas such as catheter ablation, biosurgery products and other surgical devices.

The company is awaiting approval for automated manufacture of its Evarrest patch to stop surgical bleeding that should help spur growth of that biosurgical product.

He said business was stabilizing in Europe. "Countries in Europe are starting to pay their bills, which is a good thing."

Ashley McEvoy, head of diabetes and vision care, said J&J expects to launch in 2015 a new contact lens for presbyopia, in which aging eyes have trouble focusing on close objects, and a new insulin delivery patch in the next two years.

J&J announced that its DePuy Synthes orthopedics unit was launching new products, including a shoulder repair system and a hip replacement system designed to preserve bone. In recent years the unit had been plagued by major recalls and law suits involving some of its older hip replacements.

The medical device and diagnostic division posted 2013 sales of $28.5 billion representing about 40 percent of the company's total business.

J&J shares were up 18 cents at $100.62 on the New York Stock Exchange.

(Reporting by Bill Berkrot; Editing by Meredith Mazzilli and Chris Reese)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.